Dongkook stock gains as cosmetics forecasts lift growth outlook

Published on 10/05/2026 at 18:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dongkook stock was last at KRW 22,750 on October 2, 2026, up 2.71 percent. Second-half revenue is projected at KRW 547.5 billion.

Dongkook, KR7086450004, Illustration mit AI erstellt.

Dongkook (KR7086450004) was last at KRW 22,750 on the KOSDAQ on October 2, 2026, up 2.71 percent from the prior close. The latest analyst view puts cosmetics exports at the center of the growth case, with second-half revenue projected at KRW 547.5 billion.

Cosmetics drive the forecast

According to Seoul Economic Daily on October 2, IBK Investment and Securities projects consolidated second-half revenue of KRW 547.5 billion, up 16.6 percent year over year, and operating profit of KRW 60.1 billion, up 22.5 percent. Healthcare revenue, including cosmetics, is projected at KRW 213.2 billion, an increase of 34.3 percent.

The forecast follows wider distribution in the United States and Japan. Seoul Economic Daily reports that Madeca Cream has sold more than 100 million units cumulatively, giving the Centellian24 brand a substantial domestic base as overseas retail access expands.

Q2 revenue reached KRW 259 billion

In Q2 2026, DongKook Pharmaceutical reported revenue of KRW 259 billion, up 10.9 percent year over year, and operating profit of KRW 26.1 billion, according to ATS View. The quarter's revenue was higher than Q1 2026 revenue of KRW 251 billion, while operating profit was lower than Q1's KRW 27.3 billion.

Investing.com lists a Strong Buy consensus based on one analyst. The 12-month average, high and low price target is KRW 30,000, putting the target 31.9 percent above Dongkook's October 2 price of KRW 22,750.

Stock stays below yearly high

Dongkook's October 2 range was KRW 16,260 to KRW 31,250 over 52 weeks, while volume reached 762,868 shares. Market capitalization stood at KRW 1.0 trillion on the same date, giving the cosmetics-led forecast a market value context.

For investors, the key test is whether overseas distribution can convert the projected sales growth into higher margins. The current figures show a growing top line, but the Q2 comparison with Q1 also makes operating profitability an important checkpoint.